Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation

Hypertension

Volumn 57, Issue 3, 2011, Pages 428-434

  Do Carmo, Jussara M ^a   Bassi, Mirian ^a   Da Silva, Alexandre A ^a   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; central nervous system; food intake; melanocortin system

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOTAN II; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; INSULIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALPHA-MSH; ANALYSIS OF VARIANCE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CATHETERS, INDWELLING; EATING; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERTENSION; INSULIN; LEPTIN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 3; RECEPTOR, MELANOCORTIN, TYPE 4; TELEMETRY;

EID: 79953237061     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.163931     Document Type: Article

References (32)

1. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of the melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385:165-168. (Pubitemid 27034218)
2. Hagen MM, Rushing PA, Schwartz MW, Yagaloff KA, Burn P, Woods SC, Seeley RJ. Role of the CNS melanocortin system in the response to overfeeding. J Neurosci. 1999;19:2362-2367. (Pubitemid 29133411)
3. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Target disruption of the melanocortin-4 receptor results in obesity. Cell. 1997;88:131-141. (Pubitemid 27180337)
4. Balthasar N. Genetic dissection of neuronal pathways controlling energy homeostasis. Obesity. 2006;14(Suppl 5):222S-227S.
5. Farooqi IS, O'Rahilly S. Genetic of obesity in humans. End Rev. 2006; 27:710-718.
6. Young EH, Wareham NJ, Faroqi S, Hinney A, Hebebrand J, Scherag A. O'Rahilly S, Barroso I, Sandher MS. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analyses of 29 563 individuals. Int J Obese. 2007;31:1437-1441. (Pubitemid 47339918)
7. Forooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;20:1085-1095. (Pubitemid 36337319)
8. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet. 1998;20:113-114. (Pubitemid 28455439)
9. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000;106:253-262. (Pubitemid 30483129)
10. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosc. 2003;23:5998-6004. (Pubitemid 36859438)
11. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in the control of sympathetic nerve traffic. Hypertension. 1999;33:542-547. (Pubitemid 29065717)
12. da Silva AA, do Carmo JM, Kanyicska B, Dubinion J, Brandon E, Hall JE. Endogenous melanocortin system activity contributes to the elevated arterial pressure in spontaneously hypertensive rats. Hypertension. 2008; 51:884-890. (Pubitemid 351654700)
13. Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE. Melaonocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension. 2005;46: 326-332. (Pubitemid 41099165)
14. Tallam LS, da Silva AA, Hall JE. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension. 2006;48:58-64. (Pubitemid 44297525)
15. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360:44-52.
16. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension. 2004;43:36-40. (Pubitemid 38031908)
17. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, Veneziani A, Cardillo C. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension. 2009;54:995-1000.
18. Sadler CJ, Wilding JP. Reduced ventromedial hypothalamic neuronal nitric oxide synthase and increased sensitivity to NOS inhibition in dietary obese rats: further evidence of a role for nitric oxide in the regulation of energy balance. Brain Res. 2004;1016:222-228. (Pubitemid 38887705)
19. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension. 2001;37: 670-676. (Pubitemid 32199047)
20. da Silva AA, Kuo JJ, Tallam LS, Liu J, Hall JE. Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation? Hypertension. 2006;47:259-264. (Pubitemid 43189772)
21. da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/4- receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension. 2004;43:1312-1317. (Pubitemid 38691755)
22. Horvath TL. The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci. 2005;8:561-565. (Pubitemid 40594194)
23. Fetissov SO, Xu ZQ, Byrne LC, Hassani H, Ernfors P, Hökfelt T. Neuropeptide Y targets in the hypothalamus: nitric oxide synthesizing neurons express Y1 receptor. J Neuroendocrinol. 2003;15:754-760. (Pubitemid 36874372)
24. Morley JE, Alshaher MM, Farr SA, Flood JF, Kumar VB. Leptin and neuropeptide Y (NPY) modulate nitric oxide synthase: further evidence for a role of nitric oxide in feeding. Peptides. 1999;20:595-600. (Pubitemid 29425889)
25. da Silva AA, do Carmo JM, Freeman JN, Tallam LS, Hall JE. A functional melanocortin system may be required for chronic CNS-mediated antidiabetic and cardiovascular actions of leptin. Diabetes. 2009;58: 1749-1756.
26. Adage T, Scheurink AJ, De Boer SF, De Vries K, Konsman JP, Kuipers F, Adan RA, Baskin DG, Schwartz MW, Van Dijk G. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats. J Neurosci. 2001;21:3639-3645. (Pubitemid 32422828)
27. Obici S, Feng Z, Tan J, Liu L, Karkanias G, Rossetti L. Central melanocortin receptors regulate insulin action. J Clin Invest. 2001;108: 1079-1085. (Pubitemid 32946082)
28. Frühbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 2000;48:903-908.
29. Kuo JJ, da Silva AA, Tallam LS, Hall JE. Role of adrenergic activity in pressor responses to chronic melanocortin receptor activation. Hypertension. 2004;43:370-375. (Pubitemid 38174141)
30. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004;53:2060-2066. (Pubitemid 38970755)
31. Morley JE, Mattammal MB. Nitric oxide synthase levels in obese Zucker rats. Neurosci Lett. 1996;209:137-139. (Pubitemid 26157806)
32. Qadri F, Carretero OA, Scicli AG. Centrally produced neuronal nitric oxide in the control of baroreceptor reflex sensitivity and blood pressure in normotensive and spontaneously hypertensive rats. Jpn J Pharmacol. 1999;81:279-285.